COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

BACKGROUND: Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Avouac, Jérôme, Drumez, Elodie, Hachulla, Eric, Seror, Raphaèle, Georgin-Lavialle, Sophie, El Mahou, Soumaya, Pertuiset, Edouard, Pham, Thao, Marotte, Hubert, Servettaz, Amélie, Domont, Fanny, Chazerain, Pascal, Devaux, Mathilde, Claudepierre, Pascal, Langlois, Vincent, Mekinian, Arsène, Maria, Alexandre Thibault Jacques, Banneville, Béatrice, Fautrel, Bruno, Pouchot, Jacques, Thomas, Thierry, Flipo, René-Marc, Richez, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993930/
https://www.ncbi.nlm.nih.gov/pubmed/33786454
http://dx.doi.org/10.1016/S2665-9913(21)00059-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993930/
https://www.ncbi.nlm.nih.gov/pubmed/33786454
http://dx.doi.org/10.1016/S2665-9913(21)00059-X

Ejemplares similares